Allarity Therapeutics, Inc. License Agreements
16 Contracts & Agreements
- Third Amendment to the Exclusive License Agreement with Eisai, Inc (Filed With SEC on June 7, 2023)
- Second Amendment to Development, Option & License Agreement (Filed With SEC on October 7, 2022)
- Second Amendment to License Agreement (Filed With SEC on September 30, 2022)
- Amended and Restated License Agreement among Allarity Therapeutics Europe ApS, LiPlasome Pharma ApS, and Chosa ApS dated March 28, 2022 (Filed With SEC on May 17, 2022)
- Exclusive License Agreement with Oncoheroes Bioscience, Inc. dated January 2, 2022 (Dovitnib) (Filed With SEC on May 17, 2022)
- Exclusive License Agreement with Oncoheroes Bioscience, Inc. dated January 2, 2022 (Stenoparib) (Filed With SEC on May 17, 2022)
- First Amendment to License Agreement (Filed With SEC on April 18, 2022)
- Third Amendment To Exclusive License Agreement with Smerud Medical Research International AS Dated as of September 28, 2021 (Filed With SEC on October 12, 2021)
- Second Amendment to Exclusive License Agreement between Oncology Venture, ApS and Eisai, Inc. dated as of August 3, 2021 (Filed With SEC on September 13, 2021)
- First Amendment to the Exclusive License Agreement between Eisai and Allarity Therapeutics A/S dated December 20, 2020 (Filed With SEC on September 13, 2021)
- License Agreement between Novartis Pharma Ag and Oncology Venture, ApS, dated April 6, 2018 (Filed With SEC on August 20, 2021)
- Exclusive License Agreement between Oncology Venture, ApS and Eisai, Inc., dated as of July 6, 2017 (Filed With SEC on August 20, 2021)
- Development, Option and License Agreement between Oncology Venture ApS and R-Pharm US Operating LLC, dated March 1, 2019 (Filed With SEC on August 20, 2021)
- Exclusive License Agreement between Oncology Venture, APS and 2-BBB Medicines BV, dated as of March 27, 2017 (Filed With SEC on August 20, 2021)
- Amended and Restated License Agreement between Allarity Therapeutics A/S and LiPlasome Pharma ApS, dated January 2021 (Filed With SEC on August 20, 2021)
- Exclusive License Agreement between Oncology Venture A/S and Smerud Medical Research International AS Dated as of June 26, 2020 (Filed With SEC on August 20, 2021)
